VIDEO: Rastogi discusses results of treating hyperkalemia with Lokelma
Click Here to Manage Email Alerts
Key takeaways:
- Hyperkalemia associated with renin-angiotensin-aldosterone system inhibitors therapy can be effectively managed.
- Patients with renal disease who stopped RAASi had a 73% higher risk for kidney failure.
PHILADELPHIA — Treating hyperkalemia with Lokelma (sodium polystyrene sulfonate, AstraZeneca) increased odds of patients maintaining renin-angiotensin-aldosterone system inhibitors therapy, a speaker said.
Anjay Rastogi, MD, PhD, clinical chief of nephrology at UCLA Health, disclosed that the potassium-binder more than doubled patients’ chances of continuing lifesaving renin-angiotensin-aldosterone system inhibitors (RAASi) treatment, at ASN Kidney Week.
Patients with renal disease who stopped RAASi had a 73% higher risk for progression to kidney failure within 6 months indicating potential consequences of down-titration and discontinuation of RAASi therapy, according to the findings.
The research “demonstrates two things,” Rastogi told Healio. “Number one, hyperkalemia associated with RAASi therapy can be effectively managed, and also Lokelma use was able to sustain patients on RAASi therapy.”
Reference:
ZORA real-world evidence demonstrates that Lokelma substantially increases cardiorenal patients’ chances of maintaining lifesaving RAASi therapy. https://www.astrazeneca.com/media-centre/press-releases/2023/zora-real-world-evidence-demonstrates-that-lokelma-substantially-increases-cardiorenal-patients-chances-of-maintaining-lifesaving-raasi-therapy.html. Published Nov. 2, 2023. Accessed Nov. 16, 2023.
Collapse
Read more about
Click Here to Manage Email Alerts